442 related articles for article (PubMed ID: 22451423)
1. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Lentzsch S; O'Sullivan A; Kennedy RC; Abbas M; Dai L; Pregja SL; Burt S; Boyiadzis M; Roodman GD; Mapara MY; Agha M; Waas J; Shuai Y; Normolle D; Zonder JA
Blood; 2012 May; 119(20):4608-13. PubMed ID: 22451423
[TBL] [Abstract][Full Text] [Related]
2. Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Pozzi S; Gentile M; Sacchi S; Marcheselli R; Corso A; Cocito F; Musto P; Guarini A; Minoia C; Vincelli I; Ria R; Rivolti E; Mele G; Bari A; Mazzone C; Badiali S; Marcheselli L; Palumbo A; Morabito F
Leuk Lymphoma; 2017 Mar; 58(3):552-559. PubMed ID: 27442600
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Pönisch W; Heyn S; Beck J; Wagner I; Mohren M; Hoffmann FA; Lange T; Schmalfeld M; Zehrfeld T; Schwarzer A; Winkelmann C; Edelmann T; Röhrborn R; Hebenstreit K; Al-Ali HK; Jäkel N; Niederwieser D
Br J Haematol; 2013 Jul; 162(2):202-9. PubMed ID: 23692564
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.
Ludwig H; Kasparu H; Leitgeb C; Rauch E; Linkesch W; Zojer N; Greil R; Seebacher A; Pour L; Weißmann A; Adam Z
Blood; 2014 Feb; 123(7):985-91. PubMed ID: 24227817
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Richardson PG; Weller E; Jagannath S; Avigan DE; Alsina M; Schlossman RL; Mazumder A; Munshi NC; Ghobrial IM; Doss D; Warren DL; Lunde LE; McKenney M; Delaney C; Mitsiades CS; Hideshima T; Dalton W; Knight R; Esseltine DL; Anderson KC
J Clin Oncol; 2009 Dec; 27(34):5713-9. PubMed ID: 19786667
[TBL] [Abstract][Full Text] [Related]
6. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Lau IJ; Smith D; Aitchison R; Blesing N; Roberts P; Peniket A; Yong K; Rabin N; Ramasamy K
Ann Hematol; 2015 Apr; 94(4):643-9. PubMed ID: 25345871
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Niesvizky R; Martin TG; Bensinger WI; Alsina M; Siegel DS; Kunkel LA; Wong AF; Lee S; Orlowski RZ; Wang M
Clin Cancer Res; 2013 Apr; 19(8):2248-56. PubMed ID: 23447001
[TBL] [Abstract][Full Text] [Related]
9. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
[TBL] [Abstract][Full Text] [Related]
10. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
12. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Richardson PG; Xie W; Jagannath S; Jakubowiak A; Lonial S; Raje NS; Alsina M; Ghobrial IM; Schlossman RL; Munshi NC; Mazumder A; Vesole DH; Kaufman JL; Colson K; McKenney M; Lunde LE; Feather J; Maglio ME; Warren D; Francis D; Hideshima T; Knight R; Esseltine DL; Mitsiades CS; Weller E; Anderson KC
Blood; 2014 Mar; 123(10):1461-9. PubMed ID: 24429336
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
[TBL] [Abstract][Full Text] [Related]
17. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
Wang M; Martin T; Bensinger W; Alsina M; Siegel DS; Kavalerchik E; Huang M; Orlowski RZ; Niesvizky R
Blood; 2013 Oct; 122(18):3122-8. PubMed ID: 24014245
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Richardson PG; Siegel D; Baz R; Kelley SL; Munshi NC; Laubach J; Sullivan D; Alsina M; Schlossman R; Ghobrial IM; Doss D; Loughney N; McBride L; Bilotti E; Anand P; Nardelli L; Wear S; Larkins G; Chen M; Zaki MH; Jacques C; Anderson KC
Blood; 2013 Mar; 121(11):1961-7. PubMed ID: 23243282
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine, thalidomide and dexamethasone combination therapy for relapsed/refractory myeloma patients: results of the MUKone randomized dose selection trial.
Schey S; Brown SR; Tillotson AL; Yong K; Williams C; Davies F; Morgan G; Cavenagh J; Cook G; Cook M; Orti G; Morris C; Sherratt D; Flanagan L; Gregory W; Cavet J;
Br J Haematol; 2015 Aug; 170(3):336-48. PubMed ID: 25891006
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial.
Hou J; Du X; Jin J; Cai Z; Chen F; Zhou DB; Yu L; Ke X; Li X; Wu D; Meng F; Ai H; Zhang J; Wortman-Vayn H; Chen N; Mei J; Wang J
J Hematol Oncol; 2013 Jun; 6():41. PubMed ID: 23782711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
